Key Points
Galderma entered SMI index on September 22, 2026, just 2.5 years after IPO.
H1 2026 net sales surged 24.6% year-on-year, driving full-year guidance raise to 19-21%.
L'Oréal holds 20% stake while 80% trades freely in public markets.
GALD.SW trades at CHF 163.80 with Meyka B rating and CHF 205.41 target.
Galderma (GALD.SW) began trading in the Swiss Market Index (SMI) on September 22, joining Switzerland’s 20 largest blue-chip companies. The Zug-based dermatology firm raised its 2026 net sales guidance to 19-21% growth from 17-20%, citing stronger-than-expected momentum. Net sales jumped 24.6% year-on-year in the first half of 2026, reaching CHF 5.207 billion in 2025 from CHF 4.410 billion in 2024.
Why Galderma entered the SMI now
Galderma qualified for the SMI through rapid growth since its March 2024 IPO on the SIX Swiss Exchange. The company’s inclusion reflects its scale and liquidity among Swiss-listed firms. The SMI comprises only 20 constituents, making entry a significant milestone for institutional investors tracking Switzerland’s blue-chip benchmark.
Sales acceleration and guidance boost
Net sales climbed 24.6% year-on-year at constant currency in the first half of 2026, exceeding management expectations. Galderma raised full-year 2026 guidance to 19-21% growth from 17-20% previously. The company reaffirmed Core EBITDA margin guidance of approximately 26% at constant currency, signaling margin expansion despite rapid revenue growth.
Growth drivers across three segments
Revenue gains span Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. The company credits science-led innovation, portfolio expansion, and geographic reach for momentum. L’Oréal Group holds 20% of shares, with 80% in free float, strengthening Galderma’s public market positioning.
Meyka data shows mixed technical signals
GALD.SW trades at CHF 163.80, up 3.6% on the SMI entry news. Meyka rates the stock B (Neutral) with a 12-month forecast of CHF 205.41. RSI stands at 47.08, suggesting neither overbought nor oversold conditions. The PE ratio of 55.15 reflects growth expectations, though valuation multiples remain elevated versus sector peers.
Final Thoughts
Galderma’s SMI entry caps a rapid ascent from IPO to blue-chip status in 2.5 years. With 24.6% H1 sales growth and raised guidance, the stock offers growth exposure to dermatology. Meyka’s B grade and CHF 205.41 target suggest upside, though the elevated PE warrants caution on entry timing.
FAQs
Galderma qualified through rapid growth and scale since its March 2024 IPO, meeting SMI liquidity and size criteria for Switzerland’s 20 largest listed companies.
Net sales grew 24.6% year-on-year at constant currency in the first half of 2026, prompting a full-year guidance raise to 19-21% from 17-20%.
L’Oréal Group holds 20% of Galderma’s shares, with the remaining 80% in free float among other investors.
Meyka rates GALD.SW a B (Neutral) with a 12-month forecast of CHF 205.41, implying 25.5% upside from current levels.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.
About Author
Huzaifa Zahoor
Co FounderHuzaifa Zahoor is the engineer who built Meyka. He has spent years writing Python, training AI models, and building data pipelines specifically for financial markets. His technical articles have reached over 30,000 readers on Medium, so he knows how to make complex things easy to follow. If this article touches on how the tools work, he is the person who actually built them.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)